Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards: osteoporos int 2011;22:391-420.
作者信息
Glendenning Paul
机构信息
Department of Core Clinical Pathology & Biochemistry, PathWest Royal Perth Hospital, Perth, WA 6000, Australia.
出版信息
Clin Biochem Rev. 2011 Feb;32(1):45-7.
Abstract
摘要
相似文献
1
2
3
Clinical Utility of Biochemical Marker of Bone Turnover: Fracture Risk Prediction and Bone Healing.骨转换生化标志物的临床应用：骨折风险预测与骨愈合
J Bone Metab. 2018 May;25(2):73-78. doi: 10.11005/jbm.2018.25.2.73. Epub 2018 May 31.
4
[Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability].[使用CTX-I和PINP作为骨转换标志物：国家骨健康联盟关于规范样本处理和患者准备以减少分析前变异性的建议]
Ann Biol Clin (Paris). 2018 Aug 1;76(4):373-391. doi: 10.1684/abc.2018.1363.
5
Utility of biochemical markers of bone turnover and bone mineral density in management of osteoporosis.骨转换生化标志物和骨密度在骨质疏松症管理中的效用。
Crit Rev Clin Lab Sci. 2008;45(2):221-58. doi: 10.1080/10408360801949442.
6
7
Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability.CTX-I 和 PINP 作为骨转换标志物的应用：国家骨健康联盟建议规范样本处理和患者准备，以减少分析前的变异性。
Osteoporos Int. 2017 Sep;28(9):2541-2556. doi: 10.1007/s00198-017-4082-4. Epub 2017 Jun 19.
8
Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis.骨转换生化标志物在骨质疏松症诊断、评估及治疗随访中的应用算法。
Adv Ther. 2019 Oct;36(10):2811-2824. doi: 10.1007/s12325-019-01063-9. Epub 2019 Aug 22.
9
Biomarkers for osteoporosis management: utility in diagnosis, fracture risk prediction and therapy monitoring.用于骨质疏松症管理的生物标志物：在诊断、骨折风险预测及治疗监测中的应用
Mol Diagn Ther. 2008;12(3):157-70. doi: 10.1007/BF03256280.
10
Current recommendations for laboratory testing and use of bone turnover markers in management of osteoporosis.目前关于骨质疏松症管理中实验室检测和骨转换标志物应用的建议。
Ann Lab Med. 2012 Mar;32(2):105-12. doi: 10.3343/alm.2012.32.2.105. Epub 2012 Feb 23.
引用本文的文献
1
No Interaction Effect between Interleukin-6 Polymorphisms and Acid Ash Diet with Bone Resorption Marker in Postmenopausal Women.绝经后妇女中白细胞介素-6 多态性与酸性灰饮食对骨吸收标志物无交互作用。
Int J Environ Res Public Health. 2021 Jan 19;18(2):827. doi: 10.3390/ijerph18020827.
2
Real-world bone turnover marker use: impact on treatment decisions and fracture.真实世界中骨转换标志物的应用：对治疗决策和骨折的影响。
Osteoporos Int. 2021 May;32(5):831-840. doi: 10.1007/s00198-020-05734-0. Epub 2020 Nov 24.
3
Reference Intervals for Bone Turnover Markers in Korean Healthy Women.韩国健康女性骨转换标志物的参考区间
J Bone Metab. 2020 Feb;27(1):43-52. doi: 10.11005/jbm.2020.27.1.43. Epub 2020 Feb 29.
4
MicroRNA-186 improves fracture healing through activating the bone morphogenetic protein signalling pathway by inhibiting SMAD6 in a mouse model of femoral fracture: An animal study.微小RNA-186通过抑制SMAD6激活骨形态发生蛋白信号通路促进小鼠股骨骨折愈合：一项动物研究。
Bone Joint Res. 2019 Dec 3;8(11):550-562. doi: 10.1302/2046-3758.811.BJR-2018-0251.R1. eCollection 2019 Nov.
5
Adults with pathogenic MC4R mutations have increased final height and thereby increased bone mass.患有致病性 MC4R 突变的成年人最终身高增加，从而骨量增加。
J Bone Miner Metab. 2020 Jan;38(1):117-125. doi: 10.1007/s00774-019-01034-8. Epub 2019 Aug 30.
6
Assessing bone mineralisation in children with chronic kidney disease: what clinical and research tools are available?评估慢性肾脏病儿童的骨矿化：有哪些临床和研究工具？
Pediatr Nephrol. 2020 Jun;35(6):937-957. doi: 10.1007/s00467-019-04271-1. Epub 2019 Jun 25.
7
Associations between polymorphisms of the gene and susceptibility to osteoporotic fracture in an elderly population of Han Chinese.基因多态性与汉族老年人群骨质疏松性骨折易感性的相关性研究。
Biosci Rep. 2019 Jan 18;39(1). doi: 10.1042/BSR20181505. Print 2019 Jan 31.
本文引用的文献
1
Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards.骨转换标志物用于预测骨折风险和监测骨质疏松症治疗：需要国际参考标准。
Osteoporos Int. 2011 Feb;22(2):391-420. doi: 10.1007/s00198-010-1501-1. Epub 2010 Dec 24.
2
Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009.在确定患者的依从性方面，抗骨质疏松治疗的疗效、副作用和给药途径比给药频率更为重要：对 1970 年至 2009 年发表的文章的批判性回顾。
Osteoporos Int. 2011 Mar;22(3):741-53. doi: 10.1007/s00198-010-1335-x. Epub 2010 Jun 30.
Zotero 插件